Kezar Life Sciences (KZR) Competitors $4.38 -0.01 (-0.23%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KZR vs. ADCT, THTX, SLS, ENTA, EDIT, NLTX, PROC, NMRA, LXEO, and TILShould you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include ADC Therapeutics (ADCT), Theratechnologies (THTX), SELLAS Life Sciences Group (SLS), Enanta Pharmaceuticals (ENTA), Editas Medicine (EDIT), Neoleukin Therapeutics (NLTX), Procaps Group (PROC), Neumora Therapeutics (NMRA), Lexeo Therapeutics (LXEO), and Instil Bio (TIL). These companies are all part of the "pharmaceutical products" industry. Kezar Life Sciences vs. ADC Therapeutics Theratechnologies SELLAS Life Sciences Group Enanta Pharmaceuticals Editas Medicine Neoleukin Therapeutics Procaps Group Neumora Therapeutics Lexeo Therapeutics Instil Bio ADC Therapeutics (NYSE:ADCT) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability. Which has more volatility & risk, ADCT or KZR? ADC Therapeutics has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Does the MarketBeat Community believe in ADCT or KZR? Kezar Life Sciences received 75 more outperform votes than ADC Therapeutics when rated by MarketBeat users. However, 68.89% of users gave ADC Therapeutics an outperform vote while only 57.08% of users gave Kezar Life Sciences an outperform vote. CompanyUnderperformOutperformADC TherapeuticsOutperform Votes6268.89% Underperform Votes2831.11% Kezar Life SciencesOutperform Votes13757.08% Underperform Votes10342.92% Which has stronger valuation & earnings, ADCT or KZR? Kezar Life Sciences has lower revenue, but higher earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADC Therapeutics$70.84M1.99-$240.05M-$1.65-0.86Kezar Life Sciences$7M4.57-$101.87M-$11.55-0.38 Do analysts recommend ADCT or KZR? ADC Therapeutics presently has a consensus target price of $7.75, suggesting a potential upside of 445.77%. Kezar Life Sciences has a consensus target price of $39.50, suggesting a potential upside of 801.83%. Given Kezar Life Sciences' higher possible upside, analysts clearly believe Kezar Life Sciences is more favorable than ADC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADC Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Kezar Life Sciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is ADCT or KZR more profitable? Kezar Life Sciences has a net margin of 0.00% compared to ADC Therapeutics' net margin of -300.00%. ADC Therapeutics' return on equity of 0.00% beat Kezar Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets ADC Therapeutics-300.00% N/A -61.33% Kezar Life Sciences N/A -54.95%-46.11% Does the media refer more to ADCT or KZR? In the previous week, ADC Therapeutics had 1 more articles in the media than Kezar Life Sciences. MarketBeat recorded 2 mentions for ADC Therapeutics and 1 mentions for Kezar Life Sciences. Kezar Life Sciences' average media sentiment score of 1.87 beat ADC Therapeutics' score of -0.33 indicating that Kezar Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment ADC Therapeutics Neutral Kezar Life Sciences Very Positive Do institutionals & insiders believe in ADCT or KZR? 41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 4.1% of ADC Therapeutics shares are owned by insiders. Comparatively, 9.3% of Kezar Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryKezar Life Sciences beats ADC Therapeutics on 10 of the 18 factors compared between the two stocks. Get Kezar Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZR vs. The Competition Export to ExcelMetricKezar Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$32M$6.90B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E Ratio-0.337.4522.4218.48Price / Sales4.57242.72394.10103.91Price / CashN/A65.8538.1834.62Price / Book0.176.516.774.25Net Income-$101.87M$143.21M$3.22B$248.23M7 Day Performance-4.37%3.97%3.26%3.29%1 Month Performance-10.98%0.37%0.02%2.42%1 Year Performance-46.88%2.60%18.01%5.54% Kezar Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZRKezar Life Sciences4.0311 of 5 stars$4.38-0.2%$39.50+801.8%-46.9%$32M$7M-0.3360Upcoming EarningsNews CoveragePositive NewsADCTADC Therapeutics1.5431 of 5 stars$1.22+0.4%$7.75+537.9%-67.7%$120.39M$70.84M-0.51310Upcoming EarningsTHTXTheratechnologiesN/A$2.55+1.2%N/A+118.5%$117.25M$88.67M-25.50140Short Interest ↑SLSSELLAS Life Sciences Group0.7481 of 5 stars$1.29-1.5%N/A+25.0%$117.19M$1M-1.8710ENTAEnanta Pharmaceuticals3.9297 of 5 stars$5.23+2.5%$17.25+229.8%-55.7%$111.57M$66.59M-1.06160Upcoming EarningsNews CoveragePositive NewsEDITEditas Medicine4.1665 of 5 stars$1.33+3.9%$6.83+413.8%-68.3%$111.33M$32.31M-0.52230Upcoming EarningsAnalyst UpgradeNews CoverageNLTXNeoleukin TherapeuticsN/A$11.49+6.7%N/A-61.0%$107.98MN/A-3.6990High Trading VolumePROCProcaps GroupN/A$0.95-40.3%N/A-66.4%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeNMRANeumora Therapeutics3.1513 of 5 stars$0.66+2.0%$9.29+1,306.9%-91.4%$106.75MN/A-0.35108LXEOLexeo Therapeutics2.8893 of 5 stars$3.21+18.5%$22.20+591.6%-68.4%$106.56M$650,000.00-1.0258Upcoming EarningsPositive NewsHigh Trading VolumeTILInstil Bio3.3779 of 5 stars$16.00+3.6%$114.00+612.5%+18.8%$104.94MN/A-1.38410Positive NewsGap Down Related Companies and Tools Related Companies ADCT Competitors THTX Competitors SLS Competitors ENTA Competitors EDIT Competitors NLTX Competitors PROC Competitors NMRA Competitors LXEO Competitors TIL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KZR) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kezar Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
